IRIS
SCALISE, Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.036
AS - Asia 4.277
EU - Europa 4.067
SA - Sud America 989
AF - Africa 203
Continente sconosciuto - Info sul continente non disponibili 169
OC - Oceania 7
Totale 18.748
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.746
SG - Singapore 1.468
VN - Vietnam 842
UA - Ucraina 797
BR - Brasile 732
RU - Federazione Russa 714
CN - Cina 611
TR - Turchia 433
IE - Irlanda 412
IT - Italia 390
DE - Germania 389
HK - Hong Kong 348
SE - Svezia 342
DK - Danimarca 292
FR - Francia 267
FI - Finlandia 208
KR - Corea 161
GB - Regno Unito 113
CA - Canada 111
AR - Argentina 99
CI - Costa d'Avorio 80
BD - Bangladesh 77
MX - Messico 72
IN - India 66
EC - Ecuador 43
IQ - Iraq 40
CO - Colombia 39
ID - Indonesia 35
ZA - Sudafrica 34
IR - Iran 29
JP - Giappone 28
NL - Olanda 27
PL - Polonia 27
PY - Paraguay 24
IL - Israele 22
MA - Marocco 21
CR - Costa Rica 20
VE - Venezuela 18
TT - Trinidad e Tobago 16
UZ - Uzbekistan 16
ES - Italia 14
HN - Honduras 14
EG - Egitto 13
PH - Filippine 13
PK - Pakistan 13
SV - El Salvador 13
CL - Cile 12
CW - ???statistics.table.value.countryCode.CW??? 12
TN - Tunisia 12
BE - Belgio 11
AT - Austria 10
KE - Kenya 10
PR - Porto Rico 10
GT - Guatemala 9
JO - Giordania 9
PE - Perù 9
SC - Seychelles 8
BG - Bulgaria 7
MY - Malesia 7
NI - Nicaragua 7
OM - Oman 7
RO - Romania 7
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
KZ - Kazakistan 6
LT - Lituania 6
AU - Australia 5
DO - Repubblica Dominicana 5
NP - Nepal 5
PS - Palestinian Territory 5
SA - Arabia Saudita 5
AZ - Azerbaigian 4
BO - Bolivia 4
CY - Cipro 4
DZ - Algeria 4
GP - Guadalupe 4
MD - Moldavia 4
AL - Albania 3
BH - Bahrain 3
CG - Congo 3
EE - Estonia 3
ET - Etiopia 3
EU - Europa 3
HU - Ungheria 3
JM - Giamaica 3
PA - Panama 3
PT - Portogallo 3
SN - Senegal 3
SY - Repubblica araba siriana 3
BY - Bielorussia 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
GE - Georgia 2
HR - Croazia 2
KW - Kuwait 2
LY - Libia 2
MU - Mauritius 2
NG - Nigeria 2
NO - Norvegia 2
RS - Serbia 2
Totale 18.568
Salva come PNG Salva come JPEG
Città #
Ashburn 1.632
Singapore 889
Jacksonville 783
Chandler 497
Fairfield 486
Dallas 428
Dublin 412
Boardman 368
San Jose 364
Hong Kong 334
Wilmington 285
Council Bluffs 281
Ho Chi Minh City 272
Woodbridge 229
Hanoi 216
New York 215
Houston 201
Seattle 192
Moscow 170
Cambridge 166
Princeton 165
Beijing 157
Lawrence 156
San Mateo 155
Lauterbourg 128
Ann Arbor 127
The Dalles 124
Los Angeles 107
Hefei 103
Des Moines 83
Abidjan 80
São Paulo 71
Turin 65
Milan 60
Buffalo 57
Santa Clara 53
San Diego 51
Phoenix 50
Da Nang 46
Munich 43
Orem 30
Chicago 28
Helsinki 28
Chelsea 27
Haiphong 27
Mexico City 27
London 26
Miano 26
Montreal 26
Turku 25
Shanghai 24
Izmir 23
Rio de Janeiro 22
Tokyo 22
Warsaw 20
Denver 19
Belo Horizonte 18
Atlanta 17
Johannesburg 17
Brooklyn 16
Biên Hòa 15
Chennai 15
Rome 15
Tashkent 15
Wuhan 15
Amsterdam 14
Brasília 14
Dhaka 14
Guangzhou 14
Norwalk 14
Ottawa 14
Stockholm 14
Toronto 14
Columbus 13
Hải Dương 13
Manchester 13
Nuremberg 13
San José 13
Baghdad 12
Falls Church 12
San Salvador 12
Willemstad 12
Can Tho 11
Curitiba 11
Mumbai 11
Salt Lake City 11
Asunción 10
Brussels 10
Guayaquil 10
Jakarta 10
Kilburn 10
Nairobi 10
Ninh Bình 10
Washington 10
Buenos Aires 9
Bắc Giang 9
Caracas 9
Medellín 9
Naples 9
Porto Alegre 9
Totale 11.247
Salva come PNG Salva come JPEG
Nome #
Comparative efficacy of topical versus systemic teicoplanin in experimental model of wound infections 341
Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides 277
RNAIII-inhibiting peptide in combination with the cathelicidin BMAP-28 reduces lethality in mouse models of staphylococcal sepsis 240
Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. 217
BisEDT and RIP act in synergy to prevent graft infections by resistant staphylococci. 209
Anticryptosporidial activity of paromomycin. 208
ACTIVITY OF THE NEW ANTIFUNGAL TRIAZOLE, POSACONAZOLE, AGAINST CRYPTOCOCCUS NEOFORMANS 199
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina (Durability and tolerability of long-term nevirapine-based HAART). 193
Administration of protegrin peptide IB-367 to prevent endotoxin induced mortality in bile duct ligated rats. 193
Cecropin B enhances betalactams activities in experimental rat models of gram-negative septic shock 171
Epidemiology and microbiology of surgical wound infections. 167
Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock 164
Antiendotoxin activity of antimicrobial peptides and glycopeptides. 163
[Prevalence of Toxocara spp in public playgrounds in a town of Central Italy] 161
[Giardiasis: a parasitic disease of continued topicality. Study of prevalence among a selected adult population] 160
Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus. 159
Amphibian Peptides Prevent Endotoxemia and Bacterial Translocation in Bile Duct-Ligated Rats 157
Therapeutic efficacy of intraperitoneal polymyxin B and polymyxin-like peptides alone or combined with levofloxacin in rat models of septic shock 156
Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock 152
In vitro activity of amphibian peptides alone and in combination with antimicrobial agents against multidrug-resistant pathogens isolated from surgical wound infection. 151
The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis 151
A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci. 149
Antiseptic compounds still active against bacterial strains isolated from surgical wound infections despite increasing antibiotic resistance. 148
In vitro activity of citropin 1.1 alone and in combination with clinically used antimicrobial agents against Rhodococcus equi. 147
Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. 143
Therapeutic efficacy of the magainin analogue MSI-78 in different intra-abdominal sepsis rat models. 142
Interaction of antimicrobial peptide temporin L with lipopolysaccharide in vitro and in experimental rat models of septic shock caused by gram-negative bacteria. 141
[Vascular graft infection by Staphylococcus epidermidis: efficacy of various perioperative prophylaxis protocols in an animal model]. 140
Distinctin improves the efficacies of glycopeptides and betalactams against staphylococcal biofilm in an experimental model of central venous catheter infection. 140
Mupirocin prophylaxis against methicillin-susceptible, methicillin-resistant, or vancomycin-intermediate Staphylococcus epidermidis vascular-graft infection. 139
In vitro activities of tritrpticin alone and in combination with other antimicrobial agents against Pseudomonas aeruginosa. 138
In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients. 137
In vitro activity and killing effect of citropin 1.1 against gram-positive pathogens causing skin and soft tissue infections. 136
Cationic peptides combined with betalactams reduce mortality from peritonitis in experimental rat model. 136
RNAIII-Inhibiting Peptide-Loaded Polymethylmethacrylate Prevents In Vivo Staphylococcus aureus Biofilm Formation 135
Pre-treatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection. 135
RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated Staphylococcus aureus infections. 135
Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock 133
Single-dose intraperitoneal magainins improve survival in a gram-negative-pathogen septic shock rat model. 132
Experimental study on the efficacy of combination of alpha-helical antimicrobial peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides. 131
Temporin A soaking in combination with intraperitoneal linezolid prevents vascular graft infection in a subcutaneous rat pouch model of infection with Staphylococcus epidermidis with intermediate resistance to glycopeptides. 131
Suppression of drug-resistant Staphylococcal Infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide. 130
LL-37 protects rats against lethal gram-negative sepsis. 129
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. 129
LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. 128
Comparative activities of cecropin A, melittin, and cecropin A-melittin peptide CA(1-7)M(2-9)NH2 against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. 128
Temporin A alone and in combination with imipenem reduces lethality in a mouse model of staphylococcal sepsis. 128
Comparative efficacy of quinupristin/dalfopristin, linezolid, vancomycin and ciprofloxacin in the treatment of experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock technique 127
Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection. 126
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. 126
In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients. 126
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. 125
Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. 125
RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus. 125
Neutralization of endotoxin in vitro and in vivo by Bac7(1-35), a proline-rich antibacterial peptide 124
Efficacy of quinupristin/dalfopristin in preventing vascular graft infection due to Staphylococcus epidermidis with intermediate resistance to glycopeptides. 124
RNAIII-inhibiting peptide enhances healing of wounds infected with methicillin-resistant Staphylococcus aureus. 123
Effects of the antimicrobial peptide BMAP-27 in a mouse model of obstructive jaundice stimulated by lipopolysaccharide 123
Prophylaxis against Staphylococcus aureus vascular graft infection with mupirocin-soaked, collagen-sealed dacron. 123
Temporin A is effective in MRSA-infected wounds through bactericidal activity and acceleration of wound repair in a murine model. 122
In vitro activity and killing effect of the synthetic hybrid cecropin A-melittin peptide CA(1-7)M(2-9)NH(2) on methicillin-resistant nosocomial isolates of Staphylococcus aureus and interactions with clinically used antibiotics. 121
Prophylactic efficacy of linezolid alone or combined with levofloxacin and vancomycin in a rat subcutaneous pouch model of graft infection caused by Staphylococcus epidermidis with intermediate resistance to glycopeptides. 121
Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. 121
Temporin A as a prophylactic agent against methicillin sodium-susceptible and methicillin sodium-resistant Staphylococcus epidermidis vascular graft infection. 119
In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. 118
Effect of mono-dose intraperitoneal cecropins in experimental septic shock 117
The lipopeptides Pal-Lys-Lys-NH(2) and Pal-Lys-Lys soaking alone and in combination with intraperitoneal vancomycin prevent vascular graft biofilm in a subcutaneous rat pouch model of staphylococcal infection 114
In vitro activities of tachyplesin III against Pseudomonas aeruginosa. 114
In vitro and in vivo activity of aurintricarboxylic acid preparations against Cryptosporidium parvum. 114
In vitro effect on Cryptosporidium parvum of short-term exposure to cathelicidin peptides. 114
Electrophoretic karyotyping and antifungal susceptibility patterns of Candida parapsilosis clinical isolates causing deep and superficial fungal infections 114
In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. 113
Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis. 113
Potential therapeutic role of histatin derivative P-113d in experimental rat models of Pseudomonas aeruginosa sepsis. 112
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. 112
RNAIII-inhibiting peptide and/or nisin inhibit experimental vascular graft infection with methicillin-susceptible and methicillin-resistant Staphylococcus epidermidis. 111
In- vitro activity of terbinafine, atovaquone and co-trimoxazole against Pneumocystis carinii. 111
Treatment of Staphylococcus aureus Biofilm infection by the quorum sensing inhibitor RIP 110
In vitro activity and killing effect of temporin A on nosocomial isolates of Enterococcus faecalis and interactions with clinically used antibiotics. 110
In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci. 110
In vitro activities of membrane-active peptides against gram-positive and gram-negative aerobic bacteria. 110
In-vitro activity of topoisomerase inhibitors against Pneumocystis carinii. 110
Carbapenem-induced resistance to beta-lactams in Pseudomonas aeruginosa. 109
In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species 109
Efficacy of Tachyplesin III, Colistin and Imipenem against Multiresistant Pseudomonas aeruginosa 108
Prevalence of intestinal parasites among individuals with allergic skin diseases. 108
Unusual clinical presentation of infection due to Flavimonas oryzihabitans. 108
In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum. 108
In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. 107
HIV and HBV infection in subjects referred to a dermatological clinic. 107
Efficacy of rifampin-levofloxacin as a prophylactic agent in preventing Staphylococcus epidermidis graft infection. 106
Efficacy of polycationic peptides in preventing vascular graft infection due to Staphylococcus epidermidis. 106
Therapeutic efficacy of the polymyxin-like peptide ranalexin in an experimental model of endotoxemia. 106
Prevalence and antifungal susceptibility of vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy 105
RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis. 105
Pretreatment with the protegrin IB-367 affects Gram-positive biofilm and enhances the therapeutic efficacy of linezolid in animal models of central venous catheter infection. 105
Polycationic peptides as prophylactic agents against methicillin-susceptible and methicillin-resistant Staphylococcus epidermidis vascular graft infection 105
In-vitro activity of lytic peptides, inhibitors of ion transport systems and ionophorous antibiotics against Pneumocystis carinii. 105
In vitro activity and killing effect of uperin 3.6 against gram-positive cocci isolated from immunocompromised patients. 104
Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. 104
Totale 13.572
Salva come PNG Salva come JPEG
Categoria #
all - tutte 83.255
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.255
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022764 0 0 0 0 9 105 40 63 73 192 36 246
2022/20231.652 199 166 132 117 122 179 2 80 482 8 125 40
2023/20241.001 209 18 43 189 198 194 14 7 0 4 20 105
2024/20252.336 278 197 175 112 105 148 261 92 467 98 190 213
2025/20266.600 298 564 559 831 588 401 1.143 702 655 498 78 283
2026/20271.613 261 257 358 705 32 0 0 0 0 0 0 0
Totale 18.748